American Diabetes Association

And so once we did that and we inserted our gene therapy, we found that immediately the insulin requirements essentially dropped and glucose levels normalized and they stayed normalized for a duration of about 15 to 16 weeks.

that length of time in animal testing was really significant because if you look at comparable animal testing and stem cell based approaches usually the stem cells that are placed back into the body are attacked by the immune system and killed within about you know 16 to 18 days and so the fact that we're talking weeks as opposed to days we believe already gives us a leg up now The question that everybody asked is, well, if you're delivering with an AAV, it has to be perfect, right? And so that's part of what we've been working on in the last year in kind of like a stealth mode is how do we optimize the constructs to be able to get more longer-term durable responses of our gene therapy? And at American Diabetes Association last year, we announced that we are exploring the use of lipid nanoparticles, which we've done in our oncology program for years.

But the data we announced there was really significant.

And we believe that we're the first to be able to deliver an LNP directly to the pancreas and get a gene therapy exactly in the pancreas where it's meant to go in the islets and convert those islet alpha cells into beta cells.

It's a natural way to bring down your blood glucose.

In fact, the American Diabetes Association started to address this in its 2022 update on nutritional treatments.

And it flagged it as one of the areas that is interesting for potential research.

There hasn't been a lot of research lately, but because of the intense interest in the last few years into intermittent fasting, two studies came out at the end of 2022, which suggested that indeed intermittent fasting could be used to Bring about a drug-free remission of type 2 diabetes, which is all natural.

Type 2 diabetes is a reversible disease.

The American Diabetes Association in 2021 changed.

It used to think of type 2 diabetes as a chronic and progressive disease.

That is, once you had the disease, you had it for life and there's nothing you could do about it.

But I want to keep going.

I've talked to the American Diabetes Association and They're looking for programs that have even lower dropout, longer adherence, and so I'm trying to create a program that has great dietary adherence, high program satisfaction, few dropouts.

And also, lately, the most recent recommendations from the American Diabetes Association says basically we need to prescribe these behavioral programs for people with type 2 diabetes who are motivated to lose weight.

So intervention development.

What have I been doing for the past few years? I've created a novel intervention for type 2 diabetes.

And then meetings every two months for the remaining time.

So in this study, it was a randomized trial.

This is sort of the gold standard when you're trying to compare two things, right? People are randomly put into one group or another, and they were randomly assigned the very low-carbohydrate diet classes, or they were randomly assigned an American Diabetes Association carbohydrate-counting diet.

I have no idea.

I know I'm out there with the American Diabetes Association.

That's the main thing.

They talk about the importance of good health and the disparaging amounts of African Americans that are affected by this disease.

Significant statistical significance.

And then guess where I presented that study? At the American Diabetes Association's 80th conference in Chicago.

Nice.

All the researchers involved said, look, you will never be able to present this anywhere outside India.

We published both these data sets first at ATTD 2023, which is a leading meeting from Europe.

Then last year at American Diabetes Association, we published a much larger scale a real-world study which was conducted by individual users.

We had close to 250 users from 12 plus countries who participated in this study and we published the performance which is basically against finger stick we stay around about 9% mean error against finger stick and we have close to 76% data falling within plus minus 15% of the of the finger stick reference and slightly above 1% about 1.5% data is outliers outside plus minus 40%.

And that's why we stand on glucose right now further improved, of course, because, you know, we have a very intuitive mechanism of collecting calibration data from the real world setting.

So I started looking into this and there's actually a significant amount of research showing that a low carb diet, a ketogenic diet, Starting back in the 1980s, some of this research was done.

So this has been known for a long time, which brings to mind the question, why is the only diet your doctor ever recommended to you a balanced diet? The DASH diet, the American Diabetes Association diet.

Why have they not told you about the power of a low carb diet for someone with COPD since it's been in the medical literature since the 1980s.

I'm going to link to all this research down in the show notes below so that you can do your own research and make up your own mind and perhaps even print out some of these studies and take to your doctor so that in the future, your doctor can not only take better care of you, but also take care of all their other patients with COPD or chronic bronchitis.